An ultra-sensitive and cost-effective diagnostic to improve AML patient outcome.
|Coordinator||Uppsala universitet - Institutionen för immunologi, genetik och patologi|
|Funding from Vinnova||SEK 2 200 000|
|Project duration||July 2019 - June 2021|
|Venture||Swelife and Medtech4Health - Collaborative Projects for Improved Health|
|Call||Swelife and Medtech4Health - Collaborative Projects for Improved Health (Spring 2019)|
Purpose and goal
Highly sensitive and accurate assays are needed to monitor patients with acute myeloid leukemia (AML), receiving targeted therapies. Early signs of resistance to the therapy can be met with alternate drugs. We will demonstrate that the ultrasensitive sRCA technique, earlier than competing techniques, can sense the presence of mutations heralding therapy resistance, providing a more beneficial treatment outcome. The technology can be generalized to most other malignancies.
Expected results and effects
The project will validate the sRCA technique for detection of therapy-resistant mutations for AML patients at improved sensitivity compared to competing techniques. We will also demonstrate the suitability of the sRCA technique in a clinical setting in term of assay flexibility, robustness, handling time, work load, etc.
Planned approach and implementation
In the University lab we will design and establish sRCA assays for therapy-resistant mutations in AML, and validate the assays as well as the entire work-flow using standard samples. Once the assays reach the desired performance and robustness they will be transferred to the clinical genetics lab at Uppsala University Hospital to analyze patient samples, benchmarking the technique against competing approaches in term of performance and work flow. We will evaluate the business opportunities of this new technology.